Q32 Bio (LSE:0T6G) - Stock Price, News & Analysis

0T6G Stock Overview

A clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. More details

0T6G fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	0/6
Past Performance	0/6
Financial Health	5/6
Dividends	0/6

Rewards

Analysts in good agreement that stock price will rise by 251.7%

Risk Analysis

Makes less than USD$1m in revenue ($-15M)

Earnings are forecast to decline by an average of 31.7% per year for the next 3 years

Highly volatile share price over the past 3 months compared to the UK market

Currently unprofitable and not forecast to become profitable over the next 3 years

Q32 Bio Inc. Competitors

PureTech Health

LSE:PRTC

UK£409.9m

Oxford Biomedica

LSE:OXB

UK£442.5m

Bioventix

AIM:BVXP

UK£195.7m

Faron Pharmaceuticals Oy

AIM:FARN

UK£149.1m

Price History & Performance

Summary of all time highs, changes and price drops for Q32 Bio
Historical stock prices
Current Share Price	US$25.17
52 Week High	US$53.40
52 Week Low	US$13.98
Beta	0
11 Month Change	-51.71%
3 Month Change	-33.51%
1 Year Change	n/a
33 Year Change	n/a
5 Year Change	n/a
Change since IPO	66.11%

Recent updates

Shareholder Returns

	0T6G	GB Biotechs	GB Market
7D	-24.1%	2.0%	1.7%
1Y	n/a	-17.5%	8.3%

Return vs Industry: Insufficient data to determine how 0T6G performed against the UK Biotechs industry.

Return vs Market: Insufficient data to determine how 0T6G performed against the UK Market.

Price Volatility

Is 0T6G's price volatile compared to industry and market?
0T6G volatility
0T6G Average Weekly Movement	13.0%
Biotechs Industry Average Movement	9.7%
Market Average Movement	4.8%
10% most volatile stocks in GB Market	10.3%
10% least volatile stocks in GB Market	2.6%

Stable Share Price: 0T6G's share price has been volatile over the past 3 months compared to the UK market.

Volatility Over Time: 0T6G's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of UK stocks.

About the Company

Founded	Employees	CEO	Website
2017	43	Jodie Morrison	www.q32bio.com

Q32 Bio Inc., a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis. The company is also developing Bempikibart (ADX-914), a fully human anti–interleukin-7 receptor alpha antagonist monoclonal antibody designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin that is Phase II clinical trial for the treatment of atopic dermatitis and alopecia areata.

Q32 Bio Inc. Fundamentals Summary

How do Q32 Bio's earnings and revenue compare to its market cap?
0T6G fundamental statistics
Market cap	US$299.04m
Earnings (TTM)	-US$60.61m
Revenue (TTM)	n/a

-20.4x

P/S Ratio

-4.9x

P/E Ratio

Is 0T6G overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
0T6G income statement (TTM)
Revenue	-US$14.66m
Cost of Revenue	US$45.94m
Gross Profit	-US$60.60m
Other Expenses	US$12.00k
Earnings	-US$60.61m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-4.98
Gross Margin	413.31%
Net Profit Margin	413.39%
Debt/Equity Ratio	83.5%

How did 0T6G perform over the long term?

See historical performance and comparison

Q32 Bio LSE:0T6G Stock Report